529 related articles for article (PubMed ID: 10404910)
41. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
Klages JD; Fisk JD; Rockwood K
Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
[TBL] [Abstract][Full Text] [Related]
42. Is APOE--epsilon4 a risk factor for cognitive impairment in normal aging?
Small BJ; Graves AB; McEvoy CL; Crawford FC; Mullan M; Mortimer JA
Neurology; 2000 Jun; 54(11):2082-8. PubMed ID: 10851367
[TBL] [Abstract][Full Text] [Related]
43. APOE ε4 allele is associated with worse performance in memory dimensions of the mini-mental state examination: the Bambuí Cohort Study of Aging.
Quintino-Santos S; Diniz BS; Firmo JO; Moriguchi EH; Lima-Costa MF; Castro-Costa E
Int J Geriatr Psychiatry; 2015 Jun; 30(6):573-9. PubMed ID: 25132317
[TBL] [Abstract][Full Text] [Related]
44. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
[TBL] [Abstract][Full Text] [Related]
45. Association between ApoE epsilon4 and cognitive impairment after stroke.
Wagle J; Farner L; Flekkøy K; Wyller TB; Sandvik L; Eiklid KL; Fure B; Stensrød B; Engedal K
Dement Geriatr Cogn Disord; 2009; 27(6):525-33. PubMed ID: 19494491
[TBL] [Abstract][Full Text] [Related]
46. Lower cognitive performance of older football players possessing apolipoprotein E epsilon4.
Kutner KC; Erlanger DM; Tsai J; Jordan B; Relkin NR
Neurosurgery; 2000 Sep; 47(3):651-7; discussion 657-8. PubMed ID: 10981753
[TBL] [Abstract][Full Text] [Related]
47. APOE-epsilon4 is associated with memory decline in cognitively impaired elderly.
Dik MG; Jonker C; Bouter LM; Geerlings MI; van Kamp GJ; Deeg DJ
Neurology; 2000 Apr; 54(7):1492-7. PubMed ID: 10751265
[TBL] [Abstract][Full Text] [Related]
48. The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents.
Fillenbaum GG; Landerman LR; Blazer DG; Saunders AM; Harris TB; Launer LJ
J Am Geriatr Soc; 2001 Sep; 49(9):1148-55. PubMed ID: 11559372
[TBL] [Abstract][Full Text] [Related]
49. Odor identification deficit as a predictor of five-year global cognitive change: interactive effects with age and ApoE-epsilon4.
Olofsson JK; Rönnlund M; Nordin S; Nyberg L; Nilsson LG; Larsson M
Behav Genet; 2009 Sep; 39(5):496-503. PubMed ID: 19633944
[TBL] [Abstract][Full Text] [Related]
50. Apolipoprotein E genotype and lifetime cognitive decline.
Kozauer NA; Mielke MM; Chan GK; Rebok GW; Lyketsos CG
Int Psychogeriatr; 2008 Feb; 20(1):109-23. PubMed ID: 17711604
[TBL] [Abstract][Full Text] [Related]
51. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.
Martins CA; Oulhaj A; de Jager CA; Williams JH
Neurology; 2005 Dec; 65(12):1888-93. PubMed ID: 16380608
[TBL] [Abstract][Full Text] [Related]
52. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old.
Juva K; Verkkoniemi A; Viramo P; Polvikoski T; Kainulainen K; Kontula K; Sulkava R
Neurology; 2000 Jan; 54(2):412-5. PubMed ID: 10668704
[TBL] [Abstract][Full Text] [Related]
53. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men.
Kalmijn S; Feskens EJ; Launer LJ; Kromhout D
Stroke; 1996 Dec; 27(12):2230-5. PubMed ID: 8969786
[TBL] [Abstract][Full Text] [Related]
54. Influence of apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers.
Dufouil C; Tzourio C; Brayne C; Berr C; Amouyel P; Alpérovitch A
Epidemiology; 2000 May; 11(3):280-4. PubMed ID: 10784244
[TBL] [Abstract][Full Text] [Related]
55. A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype.
Payami H; Grimslid H; Oken B; Camicioli R; Sexton G; Dame A; Howieson D; Kaye J
Am J Hum Genet; 1997 Apr; 60(4):948-56. PubMed ID: 9106542
[TBL] [Abstract][Full Text] [Related]
56. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.
Hsiung GY; Sadovnick AD; Feldman H
CMAJ; 2004 Oct; 171(8):863-7. PubMed ID: 15477624
[TBL] [Abstract][Full Text] [Related]
57. Depressive symptoms moderate the influence of the apolipoproteine epsilon4 allele on cognitive decline in a sample of community dwelling older adults.
Corsentino EA; Sawyer K; Sachs-Ericsson N; Blazer DG
Am J Geriatr Psychiatry; 2009 Feb; 17(2):155-65. PubMed ID: 19155747
[TBL] [Abstract][Full Text] [Related]
58. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study.
Peila R; White LR; Petrovich H; Masaki K; Ross GW; Havlik RJ; Launer LJ
Stroke; 2001 Dec; 32(12):2882-9. PubMed ID: 11739991
[TBL] [Abstract][Full Text] [Related]
59. Effect of APOE and CD33 on Cognitive Decline.
Hayden KM; Lutz MW; Kuchibhatla M; Germain C; Plassman BL
PLoS One; 2015; 10(6):e0130419. PubMed ID: 26102276
[TBL] [Abstract][Full Text] [Related]
60. APOE-epsilon4, depressive symptoms, and cognitive decline in Chinese older adults: Singapore Longitudinal Aging Studies.
Niti M; Yap KB; Kua EH; Ng TP
J Gerontol A Biol Sci Med Sci; 2009 Feb; 64(2):306-11. PubMed ID: 19181718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
